Mr. Barbarosh serves as Chairman of the Board of Landec and serves as an ex-officio member of the Curation Focus Committee and the Lifecore Focus Committee. Mr. Barbarosh has served as a director since October 2019. Mr. Barbarosh brings broad strategic leadership experience with deep healthcare knowledge, having served on several public companies’ boards of directors, including current board positions with NextGen Healthcare, Inc. (where he is chair of the compensation committee), Sabra Health Care REIT, Inc. (where he is chair of the audit committee) and Evolent Health, Inc. (where he is co-chair of the strategy committee). He has been recognized for successes in business strategy, operational excellence, corporate governance and capital markets transactions. Mr. Barbarosh is also a partner at the international law firm of Katten Muchin Rosenman LLP and previously was a partner of the international law firm of Pillsbury Winthrop Shaw Pittman LLP. Mr. Barbarosh received a Juris Doctorate from the University of the Pacific, McGeorge School of Law, with distinction, and a Bachelor of Arts in Business Economics from the University of California at Santa Barbara.
Dr. Calloway is an analyst and partner at 22NW, LP, a Seattle-based value fund where he has been employed since June 2021. Since October 2022, Dr. Calloway has served on the board of directors of Anebulo Pharmaceuticals, Inc., a publicly traded clinical-stage biotechnology company developing solutions for people suffering from acute cannabinoid intoxication and substance addiction. Prior to joining 22NW, LP, Dr. Calloway served in a variety of roles in healthcare research at Edison Group from December 2015 to June 2021, including as Associate Director of Healthcare Research from June 2018 to June 2021. Dr. Calloway has a Ph.D. in Chemistry and Chemical Biology from Cornell University, a Masters of Science in Chemistry from Columbia, and completed a post-doctoral study in neuroscience at Weill Cornell Medical School. He has 10 scientific publications in the areas of physical chemistry, biochemistry and neuroscience.
Mr. Diradoorian has served as a director since January 2022.  Mr. Diradoorian is a member of the Lifecore Focus Committee.  Mr. Diradoorian is a seasoned operations executive with over 40 years of experience in the pharmaceutical and medical device industries.  Mr. Diradoorian retired from Allergan Inc. in 2015, which he joined in 1983. Mr. Diradoorian held numerous positions and served as Executive Vice President of Global Technical Operations from 2006 to 2015.  Most recently, Mr. Diradoorian served as an independent industry consultant, working with a number of public and privately held companies as well private equity firms in the pharmaceutical and medical device industries.  Mr. Diradoorian holds a Bachelor of Sciences degree in Biological Sciences from the University of California at Irvine and a Masters of Science Degree in Technology Management from Pepperdine University.
Member of the Audit Committee
Mr. Edwards has served as a director since October 2020.  Currently, Mr. Edwards serves as a member of Compensation Committee and the Lifecore Focus Committee. Mr. Edwards is a member of the Board of Directors of FibroGen, Inc. (NASDAQ:FGEN), a publicly traded biopharmaceutical company, and currently serves as a chairman of its Audit Committee. Mr. Edwards serves on the Board of Directors of Bio-Rad Laboratories, Inc. (NYSE:BIO), a publicly traded life sciences research and clinical diagnostic products company, and is a member of its Audit Committee and Compliance Committee and Chairman of its Compensation Committee. Mr. Edwards also serves on the Board of Directors, Audit Committee and Compensation Committee of Clearside Biomedical Inc. (NASDAQ:CLSD), a publicly traded, clinical stage pharmaceutical company. Additionally, Mr. Edwards serves on the Board of Directors of BioTheryX, Inc., a privately owned, clinical-stage biotechnology company. In 2015 Mr. Edwards retired from Allergan Inc., which he joined in 1993 and where he served as Executive Vice President, Finance and Business Development, and Chief Financial Officer from September 2005 to August 2014. From 2003 to 2005, Mr. Edwards served as Allergan’s Corporate Vice President, Corporate Development, and previously served as Senior Vice President, Treasury, Tax, and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards received a Bachelor of Arts in Sociology from Muhlenberg College and completed the Advanced Management Program at the Harvard Business School.
Chair of the Audit Committee
James G. Hall has been the Chief Executive Officer of the Company and a member of the Board of Directors of the Company since August 10, 2022. Prior to those roles, Mr. Hall served as Vice President of the Company and President of Lifecore since June 2017. At Lifecore, Mr. Hall served as Vice President and General Manager from July 2013 to June 2017; Vice President of Operations from 2006 to 2013; Director of Manufacturing Operations and Engineering from 2001 to 2006; and the Manager of Engineering and Operations from 1999 to 2001. From 1995 until joining Lifecore in 1999, Mr. Hall was Manager of Pre-Clinical and Clinical supply for Protein Design Labs, a biotechnology company focusing on humanizing monoclonal antibodies. Prior to joining Protein Design Labs in 1995, Mr. Hall held various engineering positions within Lifecore beginning in 1989. Mr. Hall has over 33 years of pharmaceutical and combination product manufacturing and development experience.
Ms. Houde has served as a director since August 2019. Currently, Ms. Houde is the Chair of the Curation Focus Committee and a member of the Audit. Ms. Houde currently sits on the board of directors for SunOpta Inc., where she previously served as interim CEO. Ms. Houde brings extensive senior leadership experience with 30 years in the consumer products industry and a proven track record of achievements in the food industry contributing to enhanced corporate performance through effective P&L management, as well as leading successful teams and strategic initiatives in manufacturing, agribusiness and operations. Ms. Houde has also held operations management roles with Cuddy Food Products Ltd., Johnson Controls, and Scotiabank. Ms. Houde earned her Honors Bachelor of Commerce from the University of Windsor.
Member of the Compensation Committee
Mr. Kiper has served as a Co-Founder, Managing Director and the Chief Investment Officer of Legion Partners Asset Management, LLC (“Legion”) since April 2012 and at Legion’s predecessor entities from January 2010 to April 2012. Prior to co-founding Legion, Mr. Kiper served as Vice President and Portfolio Manager at Shamrock Capital Advisors from April 2007 until January 2010. Before that, Mr. Kiper founded and operated the Ridgestone Small Cap Value Fund in association with the Ridgestone Corporation, an investment firm, from June 2000 to April 2007. From 1998 to 2000, Mr. Kiper served as the Director of Financial Planning at Global Crossing Ltd., a telecommunications company that provided computer networking services. Mr. Kiper began his career as an Auditor at Ernst & Young Global Limited, an international tax, consulting and advisory service, from 1994 to 1997. Mr. Kiper received a B.S.B.A in Accounting from the University of Nebraska in 1993.
Mr. Obus has served as director since October 2018. Currently, Mr. Obus is a member of the Nominating & Corporate Governance Committee, the Compensation Committee and the Curation Focus Committee. Mr. Obus is a co-founder, President and Chief Investment Officer at Wynnefield Capital, Inc. He co-founded the firm with Joshua Landes in November 1992. Mr. Obus manages the firm, oversees its investment portfolio and is a board member at Layne Christensen Company. Previously, he was the director of research at Schafer Capital Management, Inc.  Prior to that, Mr. Obus was a director of sell side research in the equity sales department at Lazard Frères & Co. Before that, he was a manager at Massachusetts department of environmental management. Mr. Obus holds a BA in Politics from New York University as well as an MA in Political Science and an ABD in Politics from Brandeis University.
Chair of the Compensation Committee
Mr. Schechter has served as a director since October 2020. Currently, Mr. Schechter is a member of the Nominating & Corporate Governance Committee and the Curation Foods Focus Committee. He is a private investor and public company director. Mr. Schechter has served as a member of the Board of Directors of Bed Bath & Beyond (NASDAQ:BBBY) since May 2019 and is Chairman of its Audit Committee. He has also served as a director of Viad Corp (NYSE:VVI), an S&P SmallCap 600 international experiential services company, since April 2015, and as Chairman of the Board of Directors of, Inc. (NASDAQ:SPRT), a leading provider of cloud-based software and services, since June 2016. From April 2018 to January 2020 he served as Chairman of the Board of Directors of SunWorks, Inc. (NASDAQ:SUNW), a premier provider of high-performance solar power solutions. From 2001 to June 2013, Mr. Schechter served as Managing Director of Steel Partners Ltd., a privately – owned hedge fund sponsor, and from 2008 to June 2013, served as Co-President of Steel Partners Japan Asset Management, LP, a private company offering investment services. Mr. Schechter earned a Masters of Public Administration in Professional Accounting and a Bachelor of Business Administration from The University of Texas at Austin.
Member of the Nominating and Governance Committee